🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 59 of 173

  1. US 10364433

    Modulation of AGPAT5 expression

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10363319

    Glycoconjugates and methods for their use

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10363282

    Analogs of C5a and methods of using same

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10363261

    Enolase inhibitors and methods of treatment therewith

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10363237

    Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10363245

    Methods for treating CNS lesions

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10363311

    Engineered primate cystine/cysteine degrading enzymes as antineogenic agents

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10364473

    Fast diagnosis and personalized treatments for acne

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10363288

    Insulin mimotopes and methods of using the same

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10363248

    Salts of heterocyclic modulators of HIF activity for treatment of disease

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10363274

    Renal cell populations and uses thereof

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10358659

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10357217

    Method for positron emission tomography (PET) imaging analysis for classifying and diagnosing of neurological diseases

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10358419

    1,3-dipolar [70]fulleropyrrolidinium iodide derivatives

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10358421

    Piperidine derivatives as HDAC1/2 inhibitors

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10358501

    HER3 specific monoclonal antibodies for diagnostic and therapeutic use

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10357477

    Anticancer compounds

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10357464

    Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10358439

    DNA binding agents with a minor groove binding tail

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10358658

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10357510

    Metal nanoclusters and uses thereof

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10357448

    Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10357565

    Targeting microbubbles

    Expires Mon Jul 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10351878

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10351522

    Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10351597

    Peptide with anti-obesity and anti-diabetes activity and use thereof

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10350183

    Intravenous baclofen formulations and treatment methods

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10350249

    Reduction of milk glycans and their degradation products in the neonate gut

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10350267

    Polypeptide-polymer conjugates and methods of use thereof

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10351598

    Peptide with anti-obesity and anti-diabetic efficacy and use thereof

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10350228

    Treatment of sickle cell disease and inflammatory conditions

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10351580

    Acene-based transmitter molecules for photon upconversion

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10350265

    Therapeutic applications of Smad7

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10345310

    Diagnostic test for early stage cancer

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10343903

    Cationic polymer coated mesoporous silica nanoparticles and uses thereof

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10342882

    TCO conjugates and methods for delivery of therapeutic agents

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10344025

    GLS1 inhibitors for treating disease

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10343981

    Modulators of the eIF2alpha pathway

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10342822

    Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10342776

    Compositions and methods for controlling infections

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10344061

    Peptide exhibiting hair growth promoting activity and/or melanin production promoting activity and use thereof

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10344096

    Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10342869

    Compositions comprising anti-CD38 antibodies and lenalidomide

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10342771

    Creatine oral supplementation using creatine hydrochloride salt

    Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10337029

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10335458

    Pharmaceutical compositions for treating or preventing bone conditions

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10335470

    Immunogenic compositions comprising progastrin and uses thereof

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10335476

    Vaccine to protect against Ehrlichia infection

    Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.